1-5 of 5
Pamela Cohen
Close
Sort by
Journal Articles

Phase II Trial of the Tyrosine Kinase Inhibitor PKC412 in Advanced Systemic Mastocytosis: Preliminary Results.

Jason Gotlib, MD, MS, Tracy I. George, M.D., Andrea Linder, R.N., Alisa Ruddell, R.N., Sylvia Quesada, R.N., Cem Akin, M.D., Daniel J. DeAngelo, M.D.,Ph.D., Pamela Cohen, M.D., Timothy Graubert, M.D.
Journal: Blood
Blood (2006) 108 (11): 3609.
https://doi.org/10.1182/blood.V108.11.3609.3609
Published: 2006
Journal Articles

Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors

Mark Levis, Patrick Brown, B. Douglas Smith, Adam Stine, Rosalyn Pham, Richard Stone, Daniel DeAngelo, Ilene Galinsky, Frank Giles, Elihu Estey, Hagop Kantarjian, Pamela Cohen, Yanfeng Wang, Johannes Roesel, Judith E. Karp, Donald Small
Journal: Blood
Blood (2006) 108 (10): 3477–3483.
https://doi.org/10.1182/blood-2006-04-015743
Published: 2006
Journal Articles

Pharmacokinetic and Pharmacodynamic Studies of Lestaurtinib (CEP-701) and PKC-412: Cytotoxicity Is Often Dependent on Non-FLT3-Mediated Effects.

Mark Levis, MD, PhD, Adam Stine, BS, Rosalyn, Pham BS, B. Douglas Smith, MD, Judith Karp, MD, Richard Stone, MD, Elihu Estey, MD, Frank Giles, MD, Hagop Kantarjian, MD, Pamela Cohen, MD, Yanfeng Wang, PhD, Donald Small, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 2463.
https://doi.org/10.1182/blood.V106.11.2463.2463
Published: 2005
Journal Articles

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

Clinical Trials & Observations
Richard M. Stone, Daniel J. DeAngelo, Virginia Klimek, Ilene Galinsky, Eli Estey, Stephen D. Nimer, Wilson Grandin, David Lebwohl, Yanfeng Wang, Pamela Cohen, Edward A. Fox, Donna Neuberg, Jennifer Clark, D. Gary Gilliland, James D. Griffin
Journal: Blood
Blood (2005) 105 (1): 54–60.
https://doi.org/10.1182/blood-2004-03-0891
Published: 2005
Journal Articles

PKC412 Inhibits the ZNF198-FGFR1 Fusion Tyrosine Kinase and Is Efficacious in Treatment of t(8;13)(p11;q12) Associated Stem Cell Myeloproliferative Disease.

Jing Chen, Ph.D., Daniel J. DeAngelo, M.D., Jeffery L. Kutok, M.D., Ph.D., Ifor R. Williams, M.D., Ph.D., Benjamin H. Lee, M.D., Ph.D., Martha Wadleigh, M.D., Nicole Duclos, Sarah Cohen, Jennifer Adelsperger, Rachel Okabe, Allison Coburn, Ilene Galinsky, Brian J.P. Huntly, M.D., Ph.D., Pamela Cohen, Ph.D., Thomas Meyer, Ph.D., Doriano Fabbro, Ph.D., Lolita Banerji, Ph.D., James D. Griffin, M.D., Sheng Xiao, M.D., Jonathan A. Fletcher, M.D., Richard M. Stone, M.D., D. Gary Gilliland, M.D., Ph.D.
Journal: Blood
Blood (2004) 104 (11): 2549.
https://doi.org/10.1182/blood.V104.11.2549.2549
Published: 2004